PROGRAM OF STUDIES ON THE BIOLOGY AND TREATMENT OF HUMAN

目前的建议利用了丰富的临床和基础知识 达纳-法伯癌症研究所的研究资源及其 合作医院在基础和基础两个方面制定综合计划 临床研究。 该计划项目赠款的主要目标是针对 调节白血病和正常造血细胞的生长和 分化与新型免疫治疗、化疗和治疗的发展 成人和儿童白血病的移植治疗计划和 淋巴瘤。基础研究包括以下六项建议：A3) 人细胞增殖分化调控的研究进展 急性髓系白血病细胞(Griffin)。A5)C-FMS和CSF-1基因 A8)CD20、A、B在髓系分化和白血病中的表达 淋巴细胞特异性离子通道调节细胞增殖和 微分(Tedder)；A9)最小残留淋巴的检测 人类干细胞基因的N-PCR(Sklar)调控 正常细胞和白血病细胞中的细胞抗原CD34(Tenen；ALL) 淋巴细胞治疗策略(Schlossman和Breitmeyer)。一共有三个 主要临床研究项目，包括；B2)儿童急症 淋巴母细胞白血病(Sallan)；B5)多学科治疗策略 急性髓系白血病(RITZ)和B6)B细胞非霍奇金病的治疗 淋巴瘤；新的治疗策略(纳德勒)。

The present proposal takes advantage of the wealth of clinical and basic investigative resources at the Dana-Farber Cancer Institute and its collaborative hospitals to develop an integrated program in both basic and clinical research. The principal goals of this program Project Grant are directed at the regulation of both leukemic and normal hematopoietic cell growth and differentiation and the development of novel immunotherapy, chemotherapy and transplantation treatment programs for adult and childhood leukemia and lymphoma. The basic studies include the following six proposals: A3) studies on the Regulation of Proliferation and Differentiation of Human Acute Myeloblastic Leukemic Cells (Griffin). A5) C-FmS and CSF-1 Gene Expression in Myeloid Differentiation and Leukemia (Kufe); A8) CD20, A B Lymphocyte-Specific Ion Channel That Regulates Proliferation and differentiation (Tedder); A9) Detection of Minimal Residual Lymphoid neoplasia by N-PCR (Sklar); A10) Regulation of the Gene for the Human Stem Cell Antigen CD34 in Normal and Leukemic Cells (Tenen); All) Novel Lymunotherapeutic Strategies (Schlossman and Breitmeyer). There are three major clinical research projects and they include; B2) Childhood Acute Lymphoblastic Leukemia (Sallan); B5) Multi-Disciplinary Strategies for the Treatment of Acute Myeloid Leukemia (Ritz); and B6) B Cell Non-Hodgkins Lymphoma; New Therapeutic Strategies (Nadler).